CSIMarket Company Name, Ticker, Competitors, else..
 
Standard Biotools Inc   (NASDAQ: LAB)
 
Price: $0.6710 $0.02 3.231%
Day's High: $0.6869999766349792 Week Perf: 3.23 %
Day's Low: $ 0.66 30 Day Perf: -18.17 %
Volume (M): 176,577 52 Wk High: $ 1.72
Volume (M$): $ 0 52 Wk Avg: $1.11
Open: $0.66 52 Wk Low: $0.63



 Market Capitalization (Millions $) 262
 Shares Outstanding (Millions) 391
 Employees 389
 Revenues (TTM) (Millions $) 84
 Net Income (TTM) (Millions $) 85
 Cash Flow (TTM) (Millions $) 107
 Capital Exp. (TTM) (Millions $) 2

Business Description


Standard Biotools Inc is a company specializing in the development and manufacturing of biotechnology tools and solutions. They provide a range of products and services that cater to the needs of the scientific community, including research laboratories, academic institutions, and pharmaceutical companies. The company is known for its high-quality and innovative biotech tools, such as DNA sequencing kits, PCR reagents, protein purification systems, and laboratory equipment. Standard Biotools Inc aims to facilitate scientific advancements and contribute to the progress of biotechnology by providing reliable and efficient tools for researchers and scientists.


   Company Address: 50 Milk Street Boston 2109 MA
   Company Phone Number: 266-6000   Stock Exchange / Ticker: NASDAQ LAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BIO   -0.79%    
ILMN   -6.54%    
MTD   -1.74%    
QTRX   -3.36%    
RPID   -9.04%    
TXG   -3.68%    
• View Complete Report
   



Management Changes

Standard BioTools Strengthens Leadership and Financial Strategy Amidst Third Quarter Challenges

Published Thu, Nov 7 2024 1:00 PM UTC

In a move signaling its commitment to robust fiscal management and operational insight, Standard BioTools Inc. has appointed Alex Kim as Chief Financial Officer, effective November 11, 2024. This strategic decision comes against the backdrop of the company’s unveiling of its third-quarter financial results, presenting a moment of both challenge and opportunity within the c...
Merger and Acquisition

Navigating the Numbers: Standard BioTools’ Third Quarter Insights and Market Reaction

Published Wed, Oct 30 2024 8:01 PM UTC

Standard BioTools Provides Financial Snapshot for Q3 2024On October 30, 2024, Standard BioTools Inc. (NASDAQ: LAB), a player in the Laboratory Analytical Instruments sector, released its unaudited interim financial results for the third quarter ending September 30, 2024. As investors and analysts comb through these figures, several key elements emerge, shedding light on the...
Clinical Study

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)

Published Wed, Sep 18 2024 12:01 PM UTC

Comprehensive Proteomics Profiling Unveils Novel Biomarkers and Insights into Nonalcoholic Steatohepatitis (NASH)Interest in nonalcoholic steatohepatitis (NASH) has burgeoned in recent years as researchers deepen their understanding of its pathophysiology and resultant clinical sequelae. NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by li...
Contract

Standard BioTools Enhances SomaScan Platform with Cutting-Edge Carterra LSA-XT Systemb...

Published Tue, May 28 2024 8:01 PM UTC

Standard BioTools Purchases Carterra LSA-XT System to Enhance SomaScan PlatformStandard BioTools Inc., a biotechnology company, has recently acquired the LSA-XT system from Carterra, a leading provider of screening and characterization solutions for molecules. The purpose of this purchase is to further validate Standard BioTools SomaScan platform by measuring the kinetic pr...
Management Announcement

Revitalizing Operational Excellence: Standard BioTools Spearheads Biotech Innovations for a Sustainable Future

Published Thu, Apr 25 2024 12:01 PM UTC

Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
SOUTH SAN FRANCISCO, Calif., April 25, 2024 - Standard BioTools Inc. (Standard BioTools or the Company) (Nasdaq: LAB) today announced that it has initiated a restructuring plan to improve operational efficiency and reduce operating costs, while supporting the execution of the ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 3.07
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.13
Price to Sales (Expected) -
Price to Book 0.49
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.79
Working Capital Ratio 5.5
Leverage Ratio (MRQ) 0.16
Total Debt to Equity 0
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.22 $
Revenues (TTM) 0.21 $
Cash Flow (TTM) 0.27 $
Cash 0.7 $
Book Value 1.38 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 215,144
Net Income per Employee (TTM) 218,267
Receivable Turnover Ratio (TTM) 5.64
Inventory Turnover Ratio (TTM) 1.41
Asset Turnover Ratio (TTM) 0.14

Profitability Ratios Current
Gross Margin (MRQ) 52.4 %
Operating Margin (MRQ) -126.28 %
Net Margin (MRQ) -133.1 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 14.15 %
Return On Investment (TTM) 16.5 %
Return On Equity (TTM) 17.64 %
Dividend Yield -
Pay out Ratio (TTM) -



Standard Biotools Inc's Segments
Instruments    22.01 % of total Revenue
Consumables    54.09 % of total Revenue
Product revenue    76.1 % of total Revenue
Services and other revenue    28.03 % of total Revenue
Americas    38.15 % of total Revenue
EMEA    46.1 % of total Revenue
Asia-Pacific    19.87 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.